Hematological Malignancies Clinical Trial
Official title:
A Phase 1b Trial of Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Patients With Hematological Malignancies
Verified date | September 2023 |
Source | Gilead Sciences |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary objectives of this study are: - To confirm the safety and tolerability of magrolimab monotherapy in a relapsed/refractory (R/R) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) population, and of magrolimab in combination with azacitidine in previously untreated participants with AML or MDS and participants with R/R AML and MDS - To evaluate the efficacy of magrolimab monotherapy in R/R AML/MDS, and of magrolimab in combination with azacitidine in previously untreated participants with AML/MDS, or R/R AML/MDS as measured by complete remission (CR) rate for participants with AML and higher-risk MDS, and duration of complete response for participants with AML and higher-risk MDS, and duration of CR for participants with AML and higher-risk MDS - To evaluate the safety, tolerability, and efficacy of magrolimab monotherapy or combination with azacitidine in low-risk MDS participants as measured by red blood cell (RBC) transfusion independence rate
Status | Terminated |
Enrollment | 258 |
Est. completion date | September 5, 2023 |
Est. primary completion date | September 5, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Key Inclusion Criteria: - Meets the criteria below for the appropriate cohort: 1. Relapsed/Refractory Cohorts: Pathologically confirmed relapsed or refractory (primary refractory and/or relapsed refractory) AML or confirmed intermediate, high, or very high risk MDS that is relapsed, refractory or intolerant to conventional therapy 2. Treatment-naive/ Unfit Cohorts: Previously untreated individuals with histological confirmation of AML who are ineligible for treatment with a standard cytarabine and anthracycline induction regimen; or previously untreated individuals with intermediate, high, or very high risk MDS. Prior and concurrent therapy with hydroxyurea, oral etoposide, erythroid and/or myeloid growth factors is allowed. 3. Rollover Cohort: Individuals on active magrolimab therapy on the Phase 1 AML (SCI-CD47-002; NCT02678338) trial who are deriving clinical benefit by Investigator assessment 4. RBC transfusion dependent low risk MDS cohort: Transfusion-dependent MDS individuals who are very low or low risk by IPSS-R with previous treatment with an erythroid stimulating agent or lenalidomide. - White blood cell (WBC) count = 20 x 10^3/mcL - Adequate performance status and hematological, liver, and kidney function Key Exclusion Criteria: - Prior treatment with CD47 or signal regulatory protein alpha (SIRPa) targeting agents (with exception of magrolimab for individuals in the Rollover cohort). - Treatment-naive/Unfit Cohorts Only: Any prior anti-leukemic therapy (excluding hydroxyurea or oral etoposide), prior treatment with hypomethylating agents and/or low dose cytarabine. - Acute promyelocytic leukemia. - Known inherited or acquired bleeding disorders. - Previous allogeneic hematopoietic stem cell transplant within 6 months prior to enrollment, active graft versus host disease (GVHD), or requiring transplant-related immunosuppression. - Clinical suspicion of active central nervous system (CNS) involvement by leukemia - Known active or chronic hepatitis B or C infection or HIV - Pregnancy or active breastfeeding Note: Other protocol defined Inclusion/Exclusion criteria may apply. |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Oxford Centre for Respiratory Medicine Churchill Hospital, Oxford University Hospitals NHS Trust | Oxford | |
United States | University of Colorado Cancer Center | Aurora | Colorado |
United States | Dana Farber Cancer Institute/ Boston Children's Hospital | Boston | Massachusetts |
United States | Massachusetts General Hospital | Boston | Massachusetts |
United States | Montefiore Medical Center | Bronx | New York |
United States | Roswell Park Cancer Institute | Buffalo | New York |
United States | University of North Carolina at Chapel Hill | Chapel Hill | North Carolina |
United States | The University of Chicago | Chicago | Illinois |
United States | Ohio State University Medical Center | Columbus | Ohio |
United States | Texas Oncology - Baylor Charles A. Simmons Cancer Center | Dallas | Texas |
United States | City of Hope National Medical Center | Duarte | California |
United States | Duke University Medical Center | Durham | North Carolina |
United States | The University of Texas MD Anderson Cancer Center | Houston | Texas |
United States | Mid America Division, Inc. | Kansas City | Missouri |
United States | University of California San Diego (UCSD) | La Jolla | California |
United States | UCLA Clinical and Translational Research Center (CTRC) | Los Angeles | California |
United States | University Of Miami - Miller School Of Medicine, Sylvester Comprehensive Cancer Center | Miami | Florida |
United States | Medical College of WI Froedtert Hospital | Milwaukee | Wisconsin |
United States | Tennesssee Oncology - Centennial Clinic Location | Nashville | Tennessee |
United States | Herbert Irving Comprehensive Cancer Center-Columbia University Medical Center | New York | New York |
United States | Icahn School of Medicine at Mount Sinai | New York | New York |
United States | Weill Cornell Medical College - New York-Presbyterian Hospital | New York | New York |
United States | Stephenson Cancer Center | Oklahoma City | Oklahoma |
United States | Chao Family Comprehensive Cancer Center - UC Irvine Medical Center | Orange | California |
United States | University of California Davis Comprehensive Cancer Center | Sacramento | California |
United States | Stanford University Medical Center | Stanford | California |
United States | H. Lee Moffitt Cancer Center & Research Institute | Tampa | Florida |
Lead Sponsor | Collaborator |
---|---|
Gilead Sciences |
United States, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Percentage of Participant Experiencing Adverse Events | First dose date up to 4 years | ||
Primary | Complete Remission (CR) Rate For Participants With AML | The CR rate is the proportion of participants who achieved CR, as defined by the Investigator based on European Leukemia Net (ELN) AML recommendations. | Up to 4 years | |
Primary | RBC Transfusion Independence Rate for Participants with Low-Risk MDS | RBC transfusion independence rate is defined by the lack of RBC transfusions for at least an 8 week consecutive period at any time after starting therapy. | Up to 8 weeks | |
Primary | Complete Remission Rate for Participants with MDS | The CR rate is the proportion of MDS participants who reach morphologic CR while on study per International Working Group (IWG) 2006 criteria | Up to 4 years | |
Primary | Duration of Complete Remission (DCR) in Participants with AML and MDS | For AML participants: The DCR will be measured from the time measurement criteria are first met for CR (including morphologic CR, complete remission without minimal residual disease (CRMRD-), cytogenetic complete remission (cCR), and molecular complete remission (mCR) until the first date that recurrent disease or death within 8 weeks of the last response assessment with evidence of no disease recurrence is objectively documented.
For MDS participants: The DCR will be measured from the time measurement criteria are first met for CR until the first date that recurrent disease or death within 8 weeks of the last response assessment with evidence of no disease recurrence is objectively documented |
Up to 4 years | |
Secondary | Serum Concentration for Magrolimab | R/R and TN/U Cohorts: Pre-magrolimab infusion: Cycle 1 Days 1, 8, 15 & 22, Cycle 2 Days 1 & 8, every other cycle beginning with Cycle 3-Cycle 13 Day 1, End of Treatment (EOT) (after last dose of magrolimab or within 7 days of EOT decision), Safety Follow up Visit (SFU) (30 days after last dose of magrolimab); 1 hour (± 15 minutes) post magrolimab infusion: Cycle 1 Days 1 & 8, Cycle 2 Day 1, every other cycle Cycle 3-Cycle 13 Day 1
RBC MDS Cohort: Pre-magrolimab infusion: Cycle 1 Days 1, 8 & 15, Cycle 2 Days 1 & 15, every other cycle Day 1 beginning with Cycle 3 through Cycle 7 and then every third cycle through Cycle 13 Day 1; EOT; SFU; 15 minutes (± 15 minutes) post magrolimab infusion: Cycle 2 Day 1 Cycle length is 28 days Infusion Duration: 3 hours (± 30 minutes) for 1mg/kg; 2 hours for 15 mg/kg, 30 mg/kg and 60 mg/kg |
Up to 6 years | |
Secondary | Percentage of Participants who Developed Anti-Magrolimab Antibodies | R/R, TN/U Expansion, R/R MDS Cohorts: Before study drug (magrolimab or azacitidine), within 72 hours for initial dose and within 24 hours for subsequent doses Cycle 1 Days 1 and 8, Cycle 2 Day 1, Cycle 3-13 every 2 cycles Day 1, EOT (after last dose or within 7 days of EOT decision), SFU (30 days after last dose of magrolimab)
RBC MDS Cohort: Before study drug (magrolimab or azacitidine), within 72 hours for initial dose and within 24 hours for subsequent doses Cycle 1 Days 1 and 8, Cycle 2 Day 1, beginning with Cycle 3 through Cycle 7 and then every third cycle through Cycle 13 Day 1, EOT, & SFU |
Up to 6 years | |
Secondary | Percentage of AML Participants With Objective Response Based on ELN AML Recommendations | Up to 6 years | ||
Secondary | Percentage of AML Participants With Objective Response Based on IWG AML Response Criteria | Up to 6 years | ||
Secondary | Objective Response Rate (ORR) in MDS as Defined by IWG 2006 MDS Response Criteria | The ORR is the proportion of patients who reach CR (including morphologic CR, CRMRD-, cCR, and mCR), CRi, CRh, PR, marrow CR, or MLFS while on study. | Up to 6 years | |
Secondary | Duration of Response (DOR) for Participants with AML | The duration of response will be measured from the time measurement criteria are met for complete remission (CR) (including morphologic CR, complete remission without minimal residual disease (CRMRD-), cytogenetic complete remission (cCR), and molecular complete remission (mCR), incomplete blood count recovery (CRi), partial hematologic recovery (CRh), partial remission (PR), marrow CR, or morphologic leukemia-free state (MLFS), whichever is first recorded, until the first date that recurrent or progressive disease, or death within 8 weeks of the last response assessment with evidence of no disease magrolimab progression is objectively documented. | Up to 6 years | |
Secondary | Duration of Response for Participants with MDS | The DOR will be measured from the time measurement criteria are first met for objective response as assessed by IWG MDS criteria until the first date that recurrent disease or death within 8 weeks of the last response assessment with evidence of no disease recurrence is objectively documented. | Up to 6 years | |
Secondary | RBC Transfusion Independence (no RBC transfusions for at least an 8-week consecutive period) | Up to 8 weeks | ||
Secondary | 12-week RBC Transfusion Independence Rates | RBC transfusion independence rate is defined by the lack of RBC transfusions for at least an 12 week consecutive period at any time after starting therapy. | Up to 12 Weeks | |
Secondary | Mean Hemoglobin Increase on Therapy | Up to 6 years | ||
Secondary | Progression Free Survival (PFS) for Participants with AML or MDS | The length of PFS is defined as the time from the date of study treatment initiation until the date of documented disease progression or death from any cause, whichever occurs first. | Up to 6 years | |
Secondary | Relapse Free Survival (RFS) for Participants with AML or MDS | The length of RFS is defined from the first date of attaining a CR (including morphologic CR, CRMRD-, cCR, and mCR) until the date of AML relapse or death from any cause, whichever occurs first. | Up to 6 years | |
Secondary | Event Free Survival (EFS) for Participants with AML or MDS | The length of EFS is defined as the time from the date of study treatment initiation until the date of documented disease progression, death from any cause, or treatment failure (defined as permanent treatment discontinuation from any cause), whichever occurs first. | Up to 6 years | |
Secondary | Overall Survival (OS) for Participants with AML or MDS | The length of overall survival will be measured from the date of study treatment initiation until the date of death from any cause. | Up to 6 years | |
Secondary | Level of minimal residual disease (MRD) Negativity Using a Multiparameter Flow Cytometry-Based Assay for Participants on Treatment | Up to 6 years | ||
Secondary | Complete Remission with Partial Hematologic Recovery (CRh) | Up to 6 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05454241 -
CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies
|
Phase 2 | |
Recruiting |
NCT06041815 -
Correlation Between Gut Microbiota and Clinical Response to CAR-T Treatment for Hematological Malignancies
|
||
Active, not recruiting |
NCT05005442 -
A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004)
|
Phase 2 | |
Recruiting |
NCT02300571 -
Observational Study of the Combination of Post-transplant High Dose Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-versus-Host Disease in Patients Eligible to Allogeneic Hematopoietic Stem Cell Transplant
|
N/A | |
Active, not recruiting |
NCT01428973 -
Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens
|
Phase 2 | |
Completed |
NCT01162096 -
Reduced Intensity Haploidentical Transplant for Hematological Malignancies
|
Phase 1/Phase 2 | |
Completed |
NCT00379587 -
Rituximab for Prevention of Chronic GVHD
|
Phase 1/Phase 2 | |
Terminated |
NCT00506948 -
Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD)
|
Phase 2 | |
Active, not recruiting |
NCT04557098 -
A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
|
Phase 2 | |
Recruiting |
NCT04283097 -
Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects
|
Phase 1 | |
Completed |
NCT03067155 -
CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation.
|
Phase 2 | |
Completed |
NCT01725555 -
A Study to Assess the Effect of Food on the Bioavailability of the IGF-1R Inhibitor AXL1717 in Patients With Advanced Malignant Tumors
|
Phase 1 | |
Completed |
NCT00438178 -
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies
|
Phase 1 | |
Completed |
NCT03711604 -
Compassionate Use Study of Tenalisib (RP6530)
|
Phase 1/Phase 2 | |
Withdrawn |
NCT01168882 -
Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies
|
Phase 1 | |
Completed |
NCT01246206 -
Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT
|
Phase 2 | |
Completed |
NCT01172132 -
The Use of Intensive Care in Critically Ill Cancer Haematological Patients: "TRIAL-OH"
|
N/A | |
Completed |
NCT00506402 -
A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies
|
Phase 1 | |
Active, not recruiting |
NCT00163644 -
RCT to Investigate Whether an Exercise Programme Improves the Physical Performance and QOL After BMT
|
N/A | |
Completed |
NCT01063647 -
Dose-range Finding Treosulfan-based Conditioning
|
Phase 1/Phase 2 |